Business
Sanofi-Aventis makes $18.5-billion cash offer for Genzyme
Aug. 30, 2010
Biotechnology company Genzyme General Corp. said it agreed to buy drug maker GelTex Pharmaceuticals Inc. in a cash-and-stock deal worth about $1 billion.
Sept. 12, 2000
The buyer would pay $600 million and get a thriving transplant drug in the latest biotech deal.
Aug. 5, 2003
Genzyme Corp. said it had agreed to acquire AnorMED Inc. of Canada for $580 million, beating out rival biotechnology company Millennium Pharmaceuticals Inc. to gain AnorMED’s experimental blood cancer drug.
Oct. 18, 2006
Biotechnology firm Genzyme Corp. said Thursday that it was buying Ilex Oncology Inc. for $1 billion in stock to bolster its business of providing drugs to treat cancer.
Feb. 27, 2004
Booster Shots
This article was originally on a blog post platform and may be missing photos, graphics or links.
Nov. 15, 2009
Science & Medicine
Patients with Gaucher disease, who now are dependent upon one of the world’s most expensive medications, can cut treatment costs by 75% simply by reducing dosages and increasing frequency of treatment, according to researchers at the Scripps Research Institute.
Dec. 3, 1992
Inamed Corp. and its partner Genzyme Corp. won Food and Drug Administration approval of the Hylaform gel to treat wrinkles around the eyes and mouth.
April 24, 2004
Mark Piolatto, a strapping Palmdale man who not so long ago was a high school wrestling champ, a martial-arts black belt and an avid skier, has seldom taken a step in the last 10 years without pain.
June 29, 1996
DaVita Inc., the operator of dialysis centers, received a subpoena from U.S. authorities in Georgia investigating the administration of anemia drugs and vitamin D to kidney patients.
Dec. 16, 2008